Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL168920 | 0.94 | NPC1 (0.46) | NPC1LMNARAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL176089 | 0.83 | NPC1 (0.56) | NPC1LMNARAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL176199 | 0.79 | KMT2A (0.50) | NPC1LMNARAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL18701384 | 0.78 | KDM4E (0.38) | NPC1LMNARAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL167619 | 0.77 | NPC1 (0.44) | NPC1LMNARAB9AKDM4EL3MBTL1 | |
| SCHEMBL167504 | 0.76 | NPC1 (0.47) | NPC1LMNARAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL164282 | 0.73 | NPC1 (0.47) | NPC1LMNARAB9AKDM4EL3MBTL1 | |
| SCHEMBL176297 | 0.72 | NPC1 (0.57) | NPC1LMNARAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL168302 | 0.71 | NPC1 (0.56) | NPC1LMNARAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL168121 | 0.70 | NPC1 (0.73) | NPC1LMNARAB9AKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103124729-B | As the pharmaceutical active compounds of Axl inhibitor | LEAD DISCOVERY CENTER GMBH (DE) | 2016-01-20 | — | — | CN | disclosed |
| US-8999982-B2 | Pharmaceutically active compounds as Axl inhibitors | LEAD DISCOVERY CENTER GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| EP-2609091-B1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2014-11-26 | — | — | EP | disclosed |
| US-20140018365-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCCHAFTEN E.V. (DE) | 2014-01-16 | — | — | US | disclosed |
| EP-2609091-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | Lead Discovery Center GmbH (DE) | 2013-07-03 | — | — | EP | disclosed |
| CN-103124729-A | Pharmaceutically active compounds as Axl inhibitors | LEAD DISCOVERY CENTER GMBH | 2013-05-29 | — | — | CN | disclosed |
| WO-2012028332-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2012-03-08 | — | — | WO | disclosed |
| EP-2423208-A1 | Pharmaceutically active compounds as Axl inhibitors | Lead Discovery Center GmbH (DE) | 2012-02-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018365-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | AXL, FLT3, ERBB3 | NPC1 3417/4885LMNA 4125/4885RAB9A 1235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.